18-Nov-2009 - Watson Pharmaceuticals, Inc.

Watson Names Robert A. Stewart Senior Vice President, Global Operations

Watson Pharmaceuticals announced that Robert A. Stewart has joined the Company in the newly created position of Senior Vice President, Global Operations, effective immediately. In this position, Mr. Stewart will have responsibility for global manufacturing, supply chain, quality and technical operations.

The Company also announced that Thomas R. Russillo, Executive Vice President and President of the Generics Division, has been named Executive Vice President, Global Generics and will head the Company's newly formed Global Generics commercial function. In this position, Mr. Russillo will have overall responsibility for generic sales and marketing for the U.S. and Canada, as well for all international markets that will be added to Watson following completion of the acquisition of the Arrow Group. Both Mr. Stewart and Mr. Russillo report to Paul Bisaro, President and Chief Executive Officer of Watson.

Mr. Stewart joins Watson following an eight year career at Abbott Laboratories, where he most recently served as Divisional Vice President, Global Supply Chain. From 2005 until 2008 he served as Divisional Vice President, Quality Assurance. Prior to this position, Mr. Stewart was Abbott's Divisional Vice President for US/ Puerto Rico and Latin America Plant Operations, as well as Director of Operations for Abbott's Whippany plant. Prior to Abbott, he worked for Knoll Pharmaceutical Company and Hoffman La-Roche Inc.

Mr. Russillo was appointed Executive Vice President and President of the Generics Division in 2006. Prior to joining Watson, he served as a consultant to the Company in connection with the Company's integration planning related to the acquisition of Andrx. From January 2005 until September 2006 Mr. Russillo served as a consultant to various clients in the pharmaceutical industry. From 1990 through 2004, he was President of Ben Venue Laboratories, a division of Boehringer Ingelheim. Prior to Ben Venue, he held a number of senior positions with Baxter International.

Facts, background information, dossiers
  • Hoffman
  • Boehringer Ingelheim
  • Baxter
  • Andrx
More about Watson Pharmaceuticals
  • News

    Watson Completes Actavis Acquisition

    Watson Pharmaceuticals, Inc. announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion.  The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion. Watson funded ... more

    Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab

    Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, which is currently approved for treatment of breast cancer and gastric cancer. Earlier this year S ... more

    Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit

    Watson Pharmaceuticals, Inc. announced a license agreement with GeneraMedix, Inc. for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection), a drug indicated for the treatment of iron deficiency anemia in hemodialysis pati ... more

  • Companies

    Watson Pharmaceuticals, Inc.

    Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical). more